Last reviewed · How we verify

Boryung Biopharma Co., Ltd. — Portfolio Competitive Intelligence Brief

Boryung Biopharma Co., Ltd. pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
BR-TD-1001 BR-TD-1001 phase 3 Neurotrophin receptor modulator TrkA, p75NTR Neurology
DTaP-IPV combination vaccine DTaP-IPV combination vaccine phase 3 Combination vaccine Immunology
Td-pur inj Td-pur inj phase 3 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. China National Biotec Group Company Limited · 1 shared drug class
  2. GlaxoSmithKline · 1 shared drug class
  3. Jiangsu Province Centers for Disease Control and Prevention · 1 shared drug class
  4. London School of Hygiene and Tropical Medicine · 1 shared drug class
  5. MCM Vaccines B.V. · 1 shared drug class
  6. Merck Sharp & Dohme LLC · 1 shared drug class
  7. PT Bio Farma · 1 shared drug class
  8. Changchun BCHT Biotechnology Co. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Boryung Biopharma Co., Ltd.:

Cite this brief

Drug Landscape (2026). Boryung Biopharma Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/boryung-biopharma-co-ltd. Accessed 2026-05-16.

Related